Poniard Pharmaceuticals, Inc. (PARD)
Develops platinum-based cancer drugs tested in lung, colorectal, and prostate cancers.
$0.00+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+0.0%
The outlook
PARD is trading at its 52-week high, well above both its 50- and 200-day moving averages. Analyst coverage appears sparse for this micro-cap stock. The data shows a strongly positioned price trend, though investors should note the extremely low share price and limited liquidity typical of stocks at this level.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range100% of the way from its 52-week low to high
Market cap
$149
52-wk high
$0.00
52-wk low
$0.00
50-day avg
$0.00
200-day avg
$0.00
Trailing P/E
—